ARMCX4: A Potential Drug Target and Biomarker (G100131755)

Target Name: ARMCX4

NCBI ID: G100131755

ARMCX4

ARMCX4: A Potential Drug Target and Biomarker

ARMCX4 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of transmembrane protein (SMP), which includes proteins that play a crucial role in cell signaling and membrane structure. The discovery of ARMCX4 and its potential functions as a drug target and biomarker make it an attractive target for drug development.

History of ARMCX4

The study of ARMCX4 began in 2008, when a research group led by Dr. Yasmina Boudjemaa at the University of Montreal found that ARMCX4 was highly expressed in the brain and that it was involved in the development of neurodegenerative diseases, such as Alzheimer's disease. This study was the beginning of a journey that would lead to the discovery of ARMCX4's potential as a drug target and biomarker.

Expression and Localization of ARMCX4

ARMCX4 is expressed in various tissues of the body, including the brain, heart, and kidneys. It is primarily expressed in the brain, where it is involved in the development and progression of neurodegenerative diseases. Studies have shown that ARMCX4 is highly expressed in the prefrontal cortical cortex, which is the part of the brain responsible for executive functions and decision-making.

Drug Target Potential

ARMCX4's potential as a drug target is due to its unique structure and the various functions it is involved in. The SMP family of proteins has been shown to play a crucial role in cell signaling and membrane structure, and ARMCX4 is no exception. Its transmembrane structure and various functions as a protein that is involved in the formation and maintenance of the cell membrane make it an attractive target for drug development.

ARMCX4's Potential as a Biomarker

ARMCX4 has also been shown to be a potential biomarker for various diseases, including neurodegenerative diseases. Its expression is known to be involved in the development and progression of these diseases, and its decreased expression has been linked to the severity of these diseases. This makes ARMCX4 an attractive target for the development of new diagnostic tools and therapies for neurodegenerative diseases.

Discovery of ARMCX4 as a Drug Target

The discovery of ARMCX4 as a drug target began with its identification as a potential biomarker for neurodegenerative diseases. Further studies showed that ARMCX4 was involved in the development and progression of diseases such as Alzheimer's, Parkinson's, and Huntington's. This led to the development of small interfering RNA (siRNA) screens to identify potential drug targets for these diseases.

ARMCX4 has also been shown to be involved in the development of cancer, which further supports its potential as a drug target. The use of ARMCX4 as a drug target has the potential to treat a wide range of diseases, including neurodegenerative diseases, cancer, and other conditions.

Conclusion

In conclusion, ARMCX4 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its transmembrane structure and involvement in the development and progression of neurodegenerative diseases make it an attractive target for drug development. Further studies are needed to fully understand its potential as a drug target and biomarker.

Protein Name: Armadillo Repeat Containing X-linked 4

The "ARMCX4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARMCX4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets